Flag of the European Union EU Clinical Trials Register Help

Clinical trials for dexamethasone and rituximab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    50 result(s) found for: dexamethasone and rituximab. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-002711-94 Sponsor Protocol Number: HO124WM Start Date*: 2014-09-19
    Sponsor Name:HOVON Foundation
    Full Title: HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia.
    Medical condition: Waldenström's macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10054697 Waldenstrom's macroglobulinemia recurrent LLT
    21.1 100000004864 10054698 Waldenstrom's macroglobulinemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001261-33 Sponsor Protocol Number: Start Date*: 2019-11-05
    Sponsor Name:University College London
    Full Title: Randomised phase II/III study of Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as initial therapy for Waldenström's macroglobulinaemia
    Medical condition: Waldenström's macroglobulinaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-002150-64 Sponsor Protocol Number: MCL 03 Start Date*: 2004-12-22
    Sponsor Name:Medical University Vienna, Dept. of Medicine I, Clinical Division of Oncology
    Full Title: Bortezomib, Rituximab, and Dexamethasone (BORID), followed by Rituximab maintenance, for patients with relapsed/refractory mantle cell lymphoma
    Medical condition: relapsed mantle cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004498-29 Sponsor Protocol Number: 20190360 Start Date*: 2022-01-13
    Sponsor Name:Amgen Inc.
    Full Title: Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor...
    Medical condition: Newly Diagnosed Philadelphia (Ph)-negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005216-24 Sponsor Protocol Number: DSHNHL2005-1 Start Date*: 2009-06-09
    Sponsor Name:University of Saarland
    Full Title: 14-daily Oxaliplatin, Gemcitabine, Dexamethasone and Rituximab with subsequent 90-Y-Zevalin-consolidation for the treamtent of aggressive CD-20-positive B-NHL-relapses in patients with inability to...
    Medical condition: Relapse or primary progress of aggressive CD-20-positive-B-NHL
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052314 Lymphatic disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000605-84 Sponsor Protocol Number: XPORT-DLBCL-030 Start Date*: 2020-09-16
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DL...
    Medical condition: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) FR (Ongoing) IT (Trial now transitioned) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005276-14 Sponsor Protocol Number: RGCH004 Start Date*: 2016-06-03
    Sponsor Name:Sykehuset Østfold HF
    Full Title: Prolonging the response by low-dose Rituximab maintenance therapy in immune thrombocytopenia: a randomized placebo-controlled trial- the PROLONG trial.
    Medical condition: Immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DK (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003786-17 Sponsor Protocol Number: IC2012-08 Start Date*: 2013-03-29
    Sponsor Name:INSTITUT CURIE
    Full Title: Phase II study evaluating the efficacy of Lenalidomide in association with Rituximab in refractory or relapse of primary central nervous system lymphoma (PCNSL) - “Proof of concept”
    Medical condition: Primary central nervous system or Intra ocular lymphoma in relapse or refractory to previous treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10051811 Cerebral lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000219-27 Sponsor Protocol Number: 3129K4-3301-WW Start Date*: 2008-04-25
    Sponsor Name:Wyeth Pharmaceuticals Inc. acting through its division Wyeth Research, a Pfizer Company
    Full Title: An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed ...
    Medical condition: Relapsed or refractory, CD22-Positive, follicular B-cell Non Hodgkin's Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029473 Nodular (follicular) lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) PT (Prematurely Ended) DE (Completed) FR (Completed) GB (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002602-12 Sponsor Protocol Number: 16/SEP/6613E Start Date*: 2018-01-12
    Sponsor Name:Cardiff and Vale University Health Board
    Full Title: Improving Transplant Opportunities for Patients who are Sensitised (ITOPS) – a feasibility, randomised, controlled phase III trial
    Medical condition: Highly Sensitised Patients(patients with high levels of human leucocyte antigen specific antibodies) awaiting renal transplantation.These patients are difficult to match to a compatible donor and t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2005-005144-62 Sponsor Protocol Number: MCL2005-01 Start Date*: 2009-05-08
    Sponsor Name:Klinikum der Ludwigs-Maximilians-Universität München
    Full Title: Efficacy and safety of Rituximab, high-dose ARA-C and Dexamethasone (R-HAD) alone or in combination with Bortezomib in patients with relapsed or refractory mantle cell lymphoma A randomized Phase ...
    Medical condition: Treatment of relapsed or refractory Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029601 Non-Hodgkin's lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000506-37 Sponsor Protocol Number: ECWM-1 Start Date*: 2014-10-31
    Sponsor Name:University Hospital Ulm
    Full Title: Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia
    Medical condition: Waldenström's Macroglobulinemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Ongoing) PT (Prematurely Ended) SE (Completed) GR (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-000859-15 Sponsor Protocol Number: ML 18542 Start Date*: 2005-04-14
    Sponsor Name:ROCHE
    Full Title: Randomized prospective study comparing dexamethasone and dexamethasone plus rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP) in adults.
    Medical condition: Front-line treatment of adult ITP
    Disease: Version SOC Term Classification Code Term Level
    6.1 10021245 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004039-30 Sponsor Protocol Number: MCL5(MARiT) Start Date*: 2012-04-03
    Sponsor Name:PLymouth Hospitals NHS Trust
    Full Title: Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 Years
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000275-42 Sponsor Protocol Number: IIL/DLCL04 Start Date*: 2006-01-20
    Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
    Full Title: A phase III, multicentric randomized study for the treatment of young patients with unfavorable prognosis Diffuse Large Cell B Lymphoma IPI 2-3 . Dose-dense chemotherapy Rituximab +/- intens...
    Medical condition: Patients with Diffuse Large B Cell Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    10012826 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005390-21 Sponsor Protocol Number: IBDCL-GELTAMO-2015 Start Date*: 2016-02-19
    Sponsor Name:GELTAMO
    Full Title: Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab, gemcitabine, oxaliplatin and dexamethasone followed by Ibrutinib maitenance in patients w...
    Medical condition: diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003253-21 Sponsor Protocol Number: 2013-99 Start Date*: 2018-05-30
    Sponsor Name:Universitätsklinikum Münster
    Full Title: B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents
    Medical condition: mature aggressive B-cell lymphoma and leukemia in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002141-37 Sponsor Protocol Number: HOVON 80 NHL Start Date*: 2006-09-28
    Sponsor Name:HOVON foundation
    Full Title: Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-ce...
    Medical condition: relapsed B cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029547 Non-Hodgkin's lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-004540-29 Sponsor Protocol Number: Pona-CELL Start Date*: 2020-10-06
    Sponsor Name:Ústav hematologie a krevní transfuze
    Full Title: Ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph-positive acute lymphoblastic leukemia
    Medical condition: NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-022681-27 Sponsor Protocol Number: O-DEX-1 Start Date*: 2010-11-09
    Sponsor Name:University Hospital Brno
    Full Title: Ofatumumab Added to Dexamethasone in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Medical condition: Patients with refractory/relapsed CLL
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 07:16:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA